ZyVersa Therapeutics, Inc.
ZVSA- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001859007
No open-market purchases or sales by ZyVersa Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding ZyVersa Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 8 | 4 | −4 |
| Shares | 114.3K | 10.3K | −104.0K (−91.0%) |
| Value | $84.9K | $38.7K | −$46.1K (−54.3%) |
New holders (2)
Institutions that held ZyVersa Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| ADAR1 Capital Management, LLC | 9,598 | $36.1K | 0.01% |
| Bank of America Corp | 7 | $26 | 0.00% |
Sold out (6)
Institutions that held ZyVersa Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Two Sigma Securities, LLC | 31,205 | $23.4K |
| Cubist Systematic Strategies, LLC | 29,366 | $22.0K |
| UBS Group AG | 19,909 | $14.9K |
| Jane Street Group, LLC | 12,120 | $9.09K |
| HRT Financial LP | 13,176 | $9.00K |
| Wells Fargo & Company | 11 | $9 |